|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000116819 |
Summary for TFAP2E |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000116819 | Gene symbol | TFAP2E |
| Gene name | transcription factor AP-2 epsilon | |
| HGNC | 30774 | |
| Entrez ID | 339488 | |
| Gene type | protein_coding | |
| Synonyms | TFAP2E|AP2E|AP-2epsilon | |
| UniProtAcc | Q6VUC0 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TFAP2E |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for TFAP2E |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TFAP2E |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg22851880 | chr1:35573100 | CGI:chr1:35573248-35574450 | promoter | 3.61e-01 | 2.60e-01 | 2.43e+00 | 1.49e-02 | 3.12e-02 | 1.01e-01 |
| ESCA | cg14962509 | chr1:35574054 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.71e-01 | 5.59e-01 | 2.08e+00 | 3.75e-02 | 4.65e-02 | 1.11e-01 |
| CHOL | cg17474422 | chr1:35574265 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.99e-01 | 5.82e-01 | 2.10e+00 | 3.56e-02 | 4.34e-02 | 1.17e-01 |
| CHOL | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 7.32e-01 | 6.09e-01 | 2.10e+00 | 3.56e-02 | 4.34e-02 | 1.23e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg14962509 | chr1:35574054 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 5.59e-01 | 4.14e-01 | 3.05e+00 | 2.31e-03 | 3.25e-03 | 1.46e-01 |
| KIRC | cg09364688 | chr1:35573276 | CGI:chr1:35573248-35574450 | promoter | 2.14e-01 | 1.02e-01 | 5.27e+00 | 1.35e-07 | 6.43e-07 | 1.12e-01 |
| LUAD | cg17474422 | chr1:35574265 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.18e-01 | 5.18e-01 | 2.80e+00 | 5.09e-03 | 7.60e-03 | 1.00e-01 |
| LUAD | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.66e-01 | 5.52e-01 | 3.28e+00 | 1.05e-03 | 2.01e-03 | 1.14e-01 |
| HNSC | cg14962509 | chr1:35574054 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.45e-01 | 7.74e-01 | -2.28e+00 | 2.25e-02 | 2.55e-02 | -1.29e-01 |
| LUSC | cg17474422 | chr1:35574265 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.37e-01 | 4.96e-01 | 2.54e+00 | 1.11e-02 | 1.50e-02 | 1.41e-01 |
| LUSC | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.87e-01 | 5.35e-01 | 2.85e+00 | 4.38e-03 | 7.39e-03 | 1.52e-01 |
| LUSC | cg14962509 | chr1:35574054 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 7.32e-01 | 5.50e-01 | 2.44e+00 | 1.49e-02 | 1.89e-02 | 1.82e-01 |
| BLCA | cg00149492 | chr1:35572867 | CGI:chr1:35573248-35574450 | promoter | 7.66e-01 | 8.69e-01 | -2.36e+00 | 1.81e-02 | 2.26e-02 | -1.03e-01 |
| BLCA | cg11835197 | chr1:35572913 | CGI:chr1:35573248-35574450 | promoter | 4.43e-01 | 5.46e-01 | -2.58e+00 | 9.99e-03 | 1.41e-02 | -1.03e-01 |
| CHOL | cg11835197 | chr1:35572913 | CGI:chr1:35573248-35574450 | promoter | 6.09e-01 | 5.06e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.03e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg17474422 | chr1:35574265 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 8.02e-01 | 6.78e-01 | 8.99e+00 | 2.38e-19 | 1.22e-18 | 1.23e-01 |
| BRCA | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 8.28e-01 | 7.10e-01 | 9.33e+00 | 1.05e-20 | 6.00e-20 | 1.18e-01 |
| COAD | cg22851880 | chr1:35573100 | CGI:chr1:35573248-35574450 | promoter | 4.02e-01 | 2.91e-01 | 2.10e+00 | 3.55e-02 | 3.91e-02 | 1.11e-01 |
| COAD | cg11835197 | chr1:35572913 | CGI:chr1:35573248-35574450 | promoter | 5.47e-01 | 4.11e-01 | 2.93e+00 | 3.41e-03 | 7.20e-03 | 1.36e-01 |
| LIHC | cg17474422 | chr1:35574265 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 5.27e-01 | 4.23e-01 | 2.58e+00 | 9.75e-03 | 1.36e-02 | 1.04e-01 |
| LIHC | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 5.67e-01 | 4.65e-01 | 2.63e+00 | 8.58e-03 | 1.23e-02 | 1.02e-01 |
| LIHC | cg14962509 | chr1:35574054 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 6.02e-01 | 4.65e-01 | 2.45e+00 | 1.42e-02 | 1.83e-02 | 1.38e-01 |
| KIRP | cg05845757 | chr1:35574284 | CGI:chr1:35573248-35574450 | promoter,exon,CDS,gene body | 5.72e-01 | 4.30e-01 | 2.18e+00 | 2.89e-02 | 3.43e-02 | 1.42e-01 |
| KIRP | cg11835197 | chr1:35572913 | CGI:chr1:35573248-35574450 | promoter | 5.39e-01 | 4.08e-01 | 2.61e+00 | 9.00e-03 | 1.57e-02 | 1.31e-01 |
Top |
Exon skipping events with PSI in TCGA for TFAP2E |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TFAP2E |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TFAP2E |
| TFs related to TFAP2E. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | ZNF235 | TFAP2E | 4.20e+00 | 9.87e-01 | 2.91e+00 | 1.88e-03 | Male-biased |
| DLBC | ZNF287 | TFAP2E | 4.12e+00 | 9.85e-01 | 2.89e+00 | 2.34e-03 | Male-biased |
| PAAD | NRF1 | TFAP2E | 2.86e+00 | 3.03e-03 | 3.89e+00 | 9.81e-01 | Female-biased |
| PAAD | ZNF121 | TFAP2E | 2.90e+00 | 8.34e-04 | 4.17e+00 | 9.89e-01 | Female-biased |
| PAAD | ZNF181 | TFAP2E | 2.96e+00 | 1.27e-03 | 4.15e+00 | 9.88e-01 | Female-biased |
| PAAD | ZNF33A | TFAP2E | 2.93e+00 | 6.70e-04 | 4.25e+00 | 9.90e-01 | Female-biased |
| PAAD | ZNF443 | TFAP2E | 2.90e+00 | 7.70e-04 | 4.19e+00 | 9.90e-01 | Female-biased |
| PAAD | ZNF496 | TFAP2E | 2.91e+00 | 1.08e-03 | 4.13e+00 | 9.88e-01 | Female-biased |
| PAAD | ZNF519 | TFAP2E | 2.99e+00 | 2.11e-03 | 4.09e+00 | 9.86e-01 | Female-biased |
| PAAD | ZNF571 | TFAP2E | 3.03e+00 | 1.06e-03 | 4.27e+00 | 9.90e-01 | Female-biased |
| PAAD | ZNF770 | TFAP2E | 3.25e+00 | 2.10e-03 | 4.36e+00 | 9.90e-01 | Female-biased |
| SARC | ZNF121 | TFAP2E | 4.58e+00 | 9.82e-01 | 4.05e+00 | 1.20e-02 | Male-biased |
| SARC | ZNF181 | TFAP2E | 4.61e+00 | 9.82e-01 | 4.08e+00 | 1.15e-02 | Male-biased |
| SARC | ZNF33A | TFAP2E | 4.65e+00 | 9.84e-01 | 4.10e+00 | 1.06e-02 | Male-biased |
| SARC | ZNF443 | TFAP2E | 4.75e+00 | 9.87e-01 | 4.16e+00 | 8.32e-03 | Male-biased |
| SARC | ZNF496 | TFAP2E | 4.69e+00 | 9.82e-01 | 4.17e+00 | 1.32e-02 | Male-biased |
| TFAP2E related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for TFAP2E |
| RBPs related to ES in TFAP2E. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TFAP2E related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000116819 |
| CpG Site: cg12038696 | |
| Position to Gene: gene,enhancer | |
| Male Effect: - | |
| Female Effect: -0.109199587411611 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg12038696 | chr1:35577751 | gene,enhancer | -0.109199587411611 | 1.03622051606771e-05 | -0.33287329501044727 | 5.1651154199051346e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TFAP2E |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
